AFP-L3, a well-known serum biomarker of hepatocellular carcinoma (Taketa et al., 1993) determined by the ratio between fucosylated (L3) and nonfucosylated (L1 and L2) AFP, has several advantages. Here, AFP is linked to hepatocellular carcinoma.